- Home
- BCYC vs ZVRA Comparison
BCYC vs ZVRA Comparison
Compare BCYC & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BCYC | ZVRA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 476.6M | 499.4M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BCYC | ZVRA |
|---|---|---|
| Price | $6.86 | $8.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $18.73 | ★ $21.71 |
| AVG Volume (30 Days) | 244.7K | ★ 888.6K |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | $28,339,000.00 | ★ $84,388,000.00 |
| Revenue This Year | N/A | $333.25 |
| Revenue Next Year | N/A | $43.70 |
| P/E Ratio | ★ N/A | $16.51 |
| Revenue Growth | N/A | ★ 244.60 |
| 52 Week Low | $6.03 | $6.19 |
| 52 Week High | $15.47 | $13.16 |
Technical Indicators
Market Signals| Indicator | BCYC | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.59 | 54.82 |
| Support Level | $6.73 | $8.01 |
| Resistance Level | $7.28 | $8.32 |
| Average True Range (ATR) | 0.33 | 0.33 |
| MACD | -0.03 | 0.12 |
| Stochastic Oscillator | 11.96 | 94.57 |
Price Performance
Historical ComparisonAbout BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.